Early Movers: RAD, HPQ, MU, FDX, WMT & More
AIDS
featured
The latest advice was triggered by the results of a study done in Thailand that showed the AIDS drug tenofovir protected many drug users. Jonathan Mermin, director of AIDS prevention for the Centers for Disease Control and Prevention. The research by the CDC and the Thailand government was published online Wednesday by the journal Lancet.
» Read More
More
-
*ViiV Healthcare places paediatric abacavir in patent pool. *Move follows earlier sign-up to pool by Gilead Sciences. ViiV Healthcare, majority-owned by GSK, is the second research-based pharmaceutical business to sign up to the new Medicines Patent Pool, following a lead set in 2011 by Gilead Sciences.
-
Feb 1- Gilead Sciences Inc on Monday reported higher-than- expected quarterly profit and revenue as sales of its flagship HIV drugs beat Wall Street estimates. "They beat handily on the top line and they beat on the bottom line by 2 cents," while suggesting that up to $100 million in sales were due to inventory stock-up, said RBC Capital Markets analyst Michael Yee.
Most Popular Video
No reason has been given yet for the departure of founder and executive chairman George Zimmer, reports CNBC's Courtney Reagan. Zimmer has long been the face of the company.
Wednesday, 19 Jun 2013 | 10:52 AM ETCNBC's Rick Santelli, explains why he hears 'crickets" when he asks questions about Fed Chairman Bernanke's policies. "Enough is enough," he rants.
Wednesday, 19 Jun 2013 | 11:36 AM ETAre reporters lobbing "softball" questions at the Fed chairman? CNBC's Rick Santelli and the Wall Street Journal's Jon Hilsenrath, debate whether the economy continues to need quantitative easing. I'm trying to inform the public about what the Fed is up to, says Hilsenrath.